Versant’s new $400M fund will be early-stage, global and appealing to Big Pharma
Versant Ventures will start the year with a new $400 million fund. The firm is doubling-down in high potential disease areas, overlooked regions, and startups that can be acquired by Big Pharma or taken through to an IPO.